Speaker Profile
Founding CEO, The 10,000 Brains Project
Biography
Patrick Brannelly has over 20 years of experience building groundbreaking neuroscience initiatives. Most recently, he was a member of the Health & Life Sciences team at Gates Ventures, where he served as Director of Partnerships & Business Development for the nonprofit Alzheimer’s Disease Data Initiative. Prior to this, he was Managing Director of the Rainwater Charitable Foundation’s Tau Consortium, which seeks to accelerate the development of new treatments for Alzheimer’s disease and frontotemporal dementia.
Earlier in his career, Pat was co-founder and CEO of NeoCORTA and Director of Partnerships & Group Programs at Posit Science, both early-stage brain health technology ventures. He also served as a management consultant in the U.S. and Europe across the pharmaceutical, energy, and technology sectors. He currently serves as a Board member and Treasurer for Stroke Onward and Harvard Alumni in Healthcare, and is a former Assistant Professor of Entrepreneurship at California State University, Fresno.
Session Abstract – PMWC 2027 Silicon Valley
Track Chair:
David Liebeskind, UCLA
PMWC Award Ceremony
• Li-Huei Tsai, MIT Picower Institute (Pioneer)
• Thomas C. Südhof, Stanford (Nobel Laureate, Pioneer)
• David Holtzman, WashU (Pioneer)
• Henrik Zetterberg, UCL / Gothenburg (Luminary)
Featured Speakers
• Thomas C. Südhof, Stanford
• Li-Huei Tsai, MIT Picower Institute
• David Holtzman, WashU
• Henrik Zetterberg, UCL / Gothenburg
• Mark Mintun, Lilly
• Randall Bateman, WashU
• Nikolaos Mellios, Circular Genomics
• Robert Rissman, USC
• Lynn Kramer, Eisai
• Thomas F. Tropea, University of Pennsylvania
• Ari J. Green, UCSF
• Diane Chan, Mass General Brigham
• Leslie Shaw, University of Pennsylvania
• Prashanthi Vemuri, Mayo Clinic
• Kejal Kantarci, Mayo Clinic
• Dan Huddleston, Lightbox Science
• Patrick Brannelly, 10K Brains
• Allan Levey, Emory
From Blood Test to Treatment
Are we finally diagnosing Alzheimer's early enough to change care?
Precision Diagnostics Across Neurology
From biomarker to bedside across neurological disease.
Neurodegeneration Beyond Alzheimer's
Parkinson's, ALS, and FTD in the precision era.
AI & Imaging Across Neurological Disease
Precision phenotyping in stroke, epilepsy, and neurodegeneration.
Why Precision Neurology Is Not Scaling
The evidence, infrastructure, access, and workflow barriers that must be fixed.
Harnessing Brain Rhythms
Gamma oscillations, brain circuits, and the future of neurotherapy.
PMWC Hall of Impact
Previous Speakers Include
Nobel laureates, technology founders, regulators, CEOs and scientific pioneers who have taken the PMWC stage.
